Sharekhan

Syncom Formulation (India) Ltd

Fri 22/05/2026,15:56:2 | NSE : SYNCOMF

₹ 14.340.08 (0.56%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 14.39

Previous Close

₹ 14.26

Volume

1609385

Mkt Cap ( Rs. Cr)

₹1347.96

High

₹ 14.49

Low

₹ 14.19

52 Week High

₹ 23.49

52 Week Low

₹ 10.21

Book Value Per Share

₹ 4.23

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Syncom Formulation (India) Ltd

Your Vote -

Buy

76.86%

Hold

17.27%

Sell

5.87%

76.86%

1824 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

14.34

5494

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

5494

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Syncom Formulation (India) Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Syncom Formul. - Regulation 33(3)(D) Of SEBI (LODR) Regulations, 2015-Submission Of Standalone & Consolidated Audited Financi

    22 May 2026, 6:53PM Pursuant to regulation 33(3)(d) of SEBI LODR Regulations, 2015 we are pleased to submit the financials for the year ended on 31st March, 2026
  • Syncom Formul. Q4 net profit jumps 40.40% at Rs 24.57 cr

    22 May 2026, 6:50PM The company reported standalone net profit of Rs 24.57 crore for the quarter ended March 31, 2026 as compared to Rs 17.50 crore in the same period las
  • Syncom Formul. - Outcome of Board Meeting

    22 May 2026, 6:40PM Syncom Formulations (India) Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
  • Syncom Formul. - Board Meeting Outcome for Regulation 33(3)(D) Of SEBI (LODR) Regulations, 2015-Submission Of Standalone & Co

    22 May 2026, 6:34PM Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone & Consolidated Audited Financial Results alo
  • Syncom Formul. - Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations, 2015 Regarding

    13 May 2026, 4:04PM Syncom Formulations India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to co
  • Syncom Formul. - Disclosure of material issue

    4 May 2026, 6:05PM Syncom Formulations (India) Limited has informed regarding Disclosure of material issue
  • Syncom Formul. - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 Read With Master SEBI Circular HO/49/14/14(7

    4 May 2026, 6:02PM Pursuant to Reg 30 we want to inform that the company has purchased a property
  • Syncom Formul. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    16 Apr 2026, 4:50PM As of March 2026, 50.57% is owned by Indian Promoters and 49.43% by Public. <p align=justify> Top five Promoters holding highest number of shares of S
  • Syncom Formul. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Apr 2026, 1:54PM Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Syncom Formul. - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    7 Apr 2026, 4:04PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Syncom Formul. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Apr 2026, 1:50PM Certificate for compliance of regulation 74(5) of the SEBI (Depositories and participants) Regulation, 2018 for the quarter ended 31st March, 2026
  • Syncom Formul. - General Updates

    6 Apr 2026, 5:54PM Syncom Formulations (India) Limited has informed the Exchange about General Updates
  • Syncom Formul. - Forwarding Yearly Disclosure Under Regulation 31(4) Of SEBI (SAST) Regulations, 2011 By The Promoters Along

    6 Apr 2026, 5:48PM Pursuant to the regulation 31(4) of SEBI (SAST) Regulations, 2011, we would like to inform that the following promoters along with their persons actin
  • Syncom Formul. - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    3 Apr 2026, 4:07PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Syncom Formul. - Trading Window

    25 Mar 2026, 4:53PM Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) R

Key fundamentals

Evaluate the intrinsic value of Syncom Formulation (India) Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 412.9858 343.947 358.1021 339.1962 280.0124
Liabilities 412.9858 343.947 358.1021 339.1962 280.0124
Equity 94 94 94 94 86.2453
Gross Profit 77.159 53.5053 27.8543 19.6132 19.4629
Net Profit 76.008 48.8718 23.6232 20.0707 19.7904
Cash From Operating Activities 58.292 23.3133 -5.9376 10.4962 16.329
NPM(%) 15.62 10.55 9.14 8.93 9
Revenue 486.5728 462.8493 258.3596 224.6439 219.6632
Expenses 409.4138 409.344 230.5053 205.0307 200.2003
ROE(%) 19.12 12.29 5.94 5.05 4.97

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Syncom Formulation (India) Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.80 -0.07 0.00 8.18 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 109.19 1.26 352.23 29.80 3.55 0.00
Vaishali Pharma Ltd 7.00 0.14 0.00 186.95 3.13 0.00
Astec Lifesciences Ltd 771.80 4.77 0.00 28.10 -363.15 0.00

Company Info

Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.

Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.

Parent Organisation

Syncom Formulation (India) Ltd.

Founded

21/06/1988

Managing Director

Mr.Vijay Shankarlal Bankda

NSE Symbol

SYNCOMFEQ

FAQ

OPEN FREE* DEMAT ACCOUNT